Traduction et republication de:«Traitement anticoagulant de la maladie veineuse thromboembolique associée au cancer»
I Mahé, D Mayeur, F Couturaud, F Scotté… - La Revue de Médecine …, 2024 - Elsevier
Résumé La maladie thromboembolique veineuse (MTEV) est une complication fréquente et
potentiellement mortelle chez les patients atteints de cancer. Pendant la période qui suit …
potentiellement mortelle chez les patients atteints de cancer. Pendant la période qui suit …
Survival Outcomes after Placement of Inferior Vena Cava Filters in Cancer Patients: Insights from a Comprehensive Cancer Center's Experience
H Abdel-Razeq, F Tamimi, MJ Al-Jaghbeer… - Journal of Clinical …, 2023 - mdpi.com
Background: Inferior vena cava (IVC) filters serve as a vital intervention when systemic
anticoagulation proves ineffective or contraindicated, particularly in the context of cancer …
anticoagulation proves ineffective or contraindicated, particularly in the context of cancer …
[PDF][PDF] Pulmonary embolism recurrence diagnosed by endobronchial ultrasound
A Bugalho - Pulmonology, 2024 - comum.rcaap.pt
We present the case of a 69-year-old man, a heavy smoker (84 packs-per-year), with
controlled hypertension using olmesartan, who presented with dyspnea (mMRC1), left …
controlled hypertension using olmesartan, who presented with dyspnea (mMRC1), left …
Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy
GE Raskob - Bleeding, Thrombosis and Vascular Biology, 2024 - btvb.org
Anticoagulant therapy is recommended for cancer-related venous thromboembolism (VTE).
Recurrent VTE prevention is the main goal of this treatment. The majority of evidence-based …
Recurrent VTE prevention is the main goal of this treatment. The majority of evidence-based …
Venous thrombosis and malignant gynecological diseases: the place of direct oral anticoagulants in prevention
EA Ulrikh - Pharmateca, 2023 - journals.eco-vector.com
Venous thromboembolism (VTE) is a common but preventable cause of death in women
after surgery for gynecological cancer. the use of unfractionated heparins or low molecular …
after surgery for gynecological cancer. the use of unfractionated heparins or low molecular …